

AMANTADINE ER -

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE

Details

| Criteria | |
|----------|--|
| | PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. |

ANTICONVULSANTS -

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET
- BANZEL 200 MG TABLET
- BANZEL 40 MG/ML ORAL SUSPENSION
- BANZEL 400 MG TABLET
- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET
- OXTELLAR XR 150 MG TABLET,EXTENDED RELEASE
- OXTELLAR XR 300 MG TABLET,EXTENDED RELEASE
- OXTELLAR XR 600 MG TABLET,EXTENDED RELEASE
- TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE

Details

| | |
|-------------------|--|
| Criteria - | PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, OR ZONISAMIDE), WITHIN THE PAST 120 DAYS. - |
|-------------------|--|

ANTIDIABETIC AGENTS - MISCELLANEOUS -

Products Affected

Step 2:

- GLYXAMBI 10 MG-5 MG TABLET
- GLYXAMBI 25 MG-5 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS. |
|-----------------|---|

ANTI-INFLAMMATORY AGENTS - GI -

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR ANY 1 OF THE FOLLOWING: BALSALAZIDE, APRISO, DELZICOL, MESALAMINE DR 800 MG TAB, OR FORMULARY MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS. |
|-----------------|--|

ANTIPSYCHOTIC AGENTS -

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS. |
|-----------------|--|

ANTIPSYCHOTIC AGENTS II -

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

| Criteria | PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS |
|----------|---|
|----------|---|

B VERSUS D ADMINISTRATIVE STEP -

Products Affected

Step 2:

- - CYCLOPHOSPHAMIDE 25 MG CAPSULE
- - CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

| Criteria | IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG. |
|----------|--|
|----------|--|

ELUXADOLINE -

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS. |
|-----------------|---|

FIDAXOMICIN -

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS. |
|-----------------|---|

INSULIN/GLP-1 ANALOG -

Products Affected

Step 2:

- SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN
- XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN

Details

| Criteria | PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) LANTUS, LANTUS SOLOSTAR, OZEMPIC, TRESIBA, TRESIBA FLEXTOUCH, TOUJEO MAX SOLOSTAR, TOUJEO SOLOSTAR OR VICTOZA AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), COMBO SULFONYLUREA- METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS. |
|----------|---|
|----------|---|

NOVEL ORAL ANTICOAGULANTS -

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS. |
|-----------------|---|

OPHTHALMIC ANTIHISTAMINES - NO OTC -

Products Affected

Step 2:

- - ALREX 0.2 % EYE
DROPS,SUSPENSION

Details

| | |
|------------|---|
| Criteria - | PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE , CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS. - |
|------------|---|

RENIN ANGIOTENSIN SYSTEM INHIBITORS -

Products Affected

Step 2:

- - TEKTURNA HCT 150 MG-12.5 MG TABLET
- - TEKTURNA HCT 150 MG-25 MG TABLET
- - TEKTURNA HCT 300 MG-12.5 MG TABLET
- - TEKTURNA HCT 300 MG-25 MG TABLET

Details

| Criteria | PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), ACE INHIBITOR COMBINATION, GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), GENERIC ARB COMBINATION OR GENERIC DIRECT RENIN INHIBITORS WITHIN THE PAST 120 DAYS. |
|----------|---|
|----------|---|

SPRITAM -

Products Affected

Step 2:

- - SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- - SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS |
|-----------------|---|

INDEX

| | | | |
|---|------|--|------|
| ALREX 0.2 % EYE | | INVOKAMET 150 MG-500 MG | |
| DROPS,SUSPENSION | 12 - | TABLET | 3 - |
| APTIOM 200 MG TABLET | 2 - | INVOKAMET 50 MG-1,000 MG | |
| APTIOM 400 MG TABLET | 2 - | TABLET | 3 - |
| APTIOM 600 MG TABLET | 2 - | INVOKAMET 50 MG-500 MG | |
| APTIOM 800 MG TABLET | 2 - | TABLET | 3 - |
| <i>aripiprazole 10 mg disintegrating tablet</i> | 5 - | INVOKAMET XR 150 MG-1,000 MG | |
| <i>aripiprazole 15 mg disintegrating tablet</i> | 5 - | TABLET, EXTENDED RELEASE | 3 - |
| BANZEL 200 MG TABLET | 2 - | INVOKAMET XR 150 MG-500 MG | |
| BANZEL 40 MG/ML ORAL | | TABLET, EXTENDED RELEASE | 3 - |
| SUSPENSION | 2 - | INVOKAMET XR 50 MG-1,000 MG | |
| BANZEL 400 MG TABLET | 2 - | TABLET, EXTENDED RELEASE | 3 - |
| <i>clozapine 100 mg disintegrating tablet</i> | 5 - | INVOKAMET XR 50 MG-500 MG | |
| <i>clozapine 12.5 mg disintegrating tablet</i> | 5 - | TABLET, EXTENDED RELEASE | 3 - |
| <i>clozapine 150 mg disintegrating tablet</i> | 5 - | INVOKANA 100 MG TABLET | 3 - |
| <i>clozapine 200 mg disintegrating tablet</i> | 5 - | INVOKANA 300 MG TABLET | 3 - |
| <i>clozapine 25 mg disintegrating tablet</i> | 5 - | JARDIANCE 10 MG TABLET | 3 - |
| CYCLOPHOSPHAMIDE 25 MG | | JARDIANCE 25 MG TABLET | 3 - |
| CAPSULE | 7 - | <i>methotrexate sodium 2.5 mg tablet</i> | 7 - |
| CYCLOPHOSPHAMIDE 50 MG | | OSMOLEX ER 129 MG TABLET, | |
| CAPSULE | 7 - | EXTENDED RELEASE | 1 - |
| DIFICID 200 MG TABLET | 9 - | OSMOLEX ER 193 MG TABLET, | |
| DIPENTUM 250 MG CAPSULE | 4 - | EXTENDED RELEASE | 1 - |
| FANAPT 1 MG TABLET | 5 - | OSMOLEX ER 258 MG TABLET, | |
| FANAPT 10 MG TABLET | 5 - | EXTENDED RELEASE | 1 - |
| FANAPT 12 MG TABLET | 5 - | OXTELLAR XR 150 MG | |
| FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 | | TABLET,EXTENDED RELEASE | 2 - |
| MG(2) TABLETS IN A DOSE PACK | 5 - | OXTELLAR XR 300 MG | |
| FANAPT 2 MG TABLET | 5 - | TABLET,EXTENDED RELEASE | 2 - |
| FANAPT 4 MG TABLET | 5 - | OXTELLAR XR 600 MG | |
| FANAPT 6 MG TABLET | 5 - | TABLET,EXTENDED RELEASE | 2 - |
| FANAPT 8 MG TABLET | 5 - | PRADAXA 110 MG CAPSULE | 11 - |
| FYCOMPA 0.5 MG/ML ORAL | | PRADAXA 150 MG CAPSULE | 11 - |
| SUSPENSION | 2 - | PRADAXA 75 MG CAPSULE | 11 - |
| FYCOMPA 10 MG TABLET | 2 - | REXULTI 0.25 MG TABLET | 6 - |
| FYCOMPA 12 MG TABLET | 2 - | REXULTI 0.5 MG TABLET | 6 - |
| FYCOMPA 2 MG TABLET | 2 - | REXULTI 1 MG TABLET | 6 - |
| FYCOMPA 4 MG TABLET | 2 - | REXULTI 2 MG TABLET | 6 - |
| FYCOMPA 6 MG TABLET | 2 - | REXULTI 3 MG TABLET | 6 - |
| FYCOMPA 8 MG TABLET | 2 - | REXULTI 4 MG TABLET | 6 - |
| GLYXAMBI 10 MG-5 MG TABLET | 3 - | SAPHRIS 10 MG SUBLINGUAL | |
| GLYXAMBI 25 MG-5 MG TABLET | 3 - | TABLET | 5 - |
| INVOKAMET 150 MG-1,000 MG | | SAPHRIS 2.5 MG SUBLINGUAL | |
| TABLET | 3 - | TABLET | 5 - |

| | | | |
|---|------|--|------|
| SAPHRIS 5 MG SUBLINGUAL TABLET..... | 5 - | VRAYLAR 3 MG CAPSULE..... | 5 - |
| SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN..... | 10 - | VRAYLAR 4.5 MG CAPSULE..... | 5 - |
| SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION..... | 14 - | VRAYLAR 6 MG CAPSULE..... | 5 - |
| SPRITAM 250 MG TABLET FOR ORAL SUSPENSION..... | 14 - | XATMEP 2.5 MG/ML ORAL SOLUTION..... | 7 - |
| SPRITAM 500 MG TABLET FOR ORAL SUSPENSION..... | 14 - | XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN..... | 10 - |
| SPRITAM 750 MG TABLET FOR ORAL SUSPENSION..... | 14 - | | |
| SYNJARDY 12.5 MG-1,000 MG TABLET..... | 3 - | | |
| SYNJARDY 12.5 MG-500 MG TABLET..... | 3 - | | |
| SYNJARDY 5 MG-1,000 MG TABLET..... | 3 - | | |
| SYNJARDY 5 MG-500 MG TABLET..... | 3 - | | |
| SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE..... | 3 - | | |
| SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE..... | 3 - | | |
| SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE..... | 3 - | | |
| SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE..... | 3 - | | |
| TEKTURNA HCT 150 MG-12.5 MG TABLET..... | 13 - | | |
| TEKTURNA HCT 150 MG-25 MG TABLET..... | 13 - | | |
| TEKTURNA HCT 300 MG-12.5 MG TABLET..... | 13 - | | |
| TEKTURNA HCT 300 MG-25 MG TABLET..... | 13 - | | |
| TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE..... | 2 - | | |
| VERSACLOZ 50 MG/ML ORAL SUSPENSION..... | 5 - | | |
| VIBERZI 100 MG TABLET..... | 8 - | | |
| VIBERZI 75 MG TABLET..... | 8 - | | |
| VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK..... | 5 - | | |
| VRAYLAR 1.5 MG CAPSULE..... | 5 - | | |